TrialJournal of the European Academy of Dermatology and Venereology : JEADV2019

Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial.

B E Elewski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.